Skip to content
Disclosery

Fairmount Funds Management LLC

Follow

13F filer, CIK 1802528, WEST CONSHOHOCKEN, PA

Fairmount Funds Management LLC reported $644,620,652 across 15 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-15. Its ten largest share positions make up 87.27% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-25-049337

Period
2025-03-31
Reported value
$645M
Holdings
15
Top 10 weight
87.27%
New
0
Sold out
2

Part of the filer group Fairmount Funds Management LLC

  • Fairmount Healthcare Fund II L.P.
  • Harwin Peter Evan
  • Kiselak Tomas
How groups are built

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AXSMreduced-653,807-$76.3M
NUVLreduced-590,101-$41.8M
DAWNexited-3,103,448-$39.3M
KNSAreduced-1,092,093-$24.3M
ANABexited-1,816,466-$24.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0001104659-25-049337, largest first. % of portfolio is the value over $644,620,652, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,360,077 shares; 2024Q4: 1,468,983 shares; 2025Q1: 815,176 shares 815,176$95.1M14.75%-653,807Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,048,647 shares; 2024Q4: 2,048,647 shares; 2025Q1: 2,048,647 shares 2,048,647$76.5M11.87%0Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,018,101 shares; 2024Q4: 4,018,101 shares; 2025Q1: 4,018,101 shares 4,018,101$64.8M10.06%02026-10-07, 13D/A: 10,185,961 shares, 9.99% of the class, 13D/A filed 2026-10-09 Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,202,798 shares; 2024Q4: 3,202,798 shares; 2025Q1: 3,202,798 shares 3,202,798$63M9.78%0Timeline
NUVLNUVALENT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,687,064 shares; 2024Q4: 1,317,664 shares; 2025Q1: 727,563 shares 727,563$51.6M8%-590,101Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,700,691 shares; 2024Q4: 2,700,691 shares; 2025Q1: 2,700,691 shares 2,700,691$49M7.6%0Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,445,813 shares; 2024Q4: 3,445,813 shares; 2025Q1: 3,445,813 shares 3,445,813$46.4M7.21%0Timeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,962,953 shares; 2025Q1: 1,374,031 shares 1,374,031$44.2M6.85%-588,922Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,225,641 shares; 2024Q4: 6,225,641 shares; 2025Q1: 6,225,641 shares 6,225,641$37.3M5.79%0Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,211,922 shares; 2024Q4: 3,371,922 shares; 2025Q1: 3,371,922 shares 3,371,922$34.6M5.37%0Timeline
KNSAKINIKSA PHARMACEUTICALS INTLQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,204,841 shares; 2024Q4: 2,194,341 shares; 2025Q1: 1,102,248 shares 1,102,248$24.5M3.8%-1,092,093Timeline
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,554,129 shares; 2024Q4: 3,554,129 shares; 2025Q1: 3,554,129 shares 3,554,129$19M2.94%0
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,892,806 shares; 2024Q4: 1,892,806 shares; 2025Q1: 1,892,806 shares 1,892,806$15M2.32%0Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 6,125,000 shares; 2025Q1: 6,125,000 shares 6,125,000$13.4M2.08%0Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,284,169 shares; 2024Q4: 1,284,169 shares; 2025Q1: 784,170 shares 784,170$10.2M1.59%-499,999Timeline

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
DAWNDAY ONE BIOPHARMACEUTICALS I3,103,448$39.3Mshares
ANABANAPTYSBIO INC1,816,466$24.1Mshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-25-049337 base2025-05-15acceptance time not in the bulk data set